Neural stem cells and human induced pluripotent stem cells to model rare CNS diseases

CNS and Neurological Disorders - Drug Targets

Volumn 16, Issue 8, 2017, Pages 915-926

  De Filippis, Lidia ^a   Zalfa, Cristina ^b   Ferrari, Daniela ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Alzheimer s disease; Amyotrophic Lateral Sclerosis; Central nervous system; Disease modeling; Embryonic stem cells; Enzyme replacement therapy; Glycosaminoglycans; Huntington s disease; Iduronate 2 Sulfatase; Induced pluripotent cells; Lysosomal storage diseases; Motor Neuron diseases; Mucopolysaccharidosis; Mucopolysaccharidosis Type II or Huner Syndrome; Neural stem cells; Neurological disorders; Parkinson s disease; Rare CNS diseases; Spinal cord; Stem cells; Sub granular Zone; Sub Ventricular zone

Indexed keywords

GLYCOSAMINOGLYCAN;

AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; AUTOTRANSPLANTATION; CENTRAL NERVOUS SYSTEM; ENZYME REPLACEMENT; GENE EDITING; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; LYSOSOME STORAGE DISEASE; METABOLIC DISORDER; MOTOR NEURON DISEASE; NEURAL STEM CELL; NUCLEAR REPROGRAMMING; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE MODEL; PHYSIOLOGY; PROCEDURES; RARE DISEASE; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEURAL STEM CELLS; RARE DISEASES; STEM CELL TRANSPLANTATION;

EID: 85027400819     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527316666170615121753     Document Type: Review

References (140)

1. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006; 139(3): 791-4.
2. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66(5): 646-61.
3. Gispert S, Del Turco D, Garrett L, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003; 24(2): 419-29.
4. Gispert S, Ricciardi F, Kurz A, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009; 4(6): e5777.
5. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2011; 10(12): 1108-18.
6. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255(5052): 1707-10.
7. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2(12): 3081-9.
8. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
9. Hargus G, Ehrlich M, Hallmann AL, Kuhlmann T. Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathol 2014; 127(2): 151-73.
10. Vescovi AL, Snyder EY. Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Brain Pathol 1999; 9(3): 569-98.
11. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; 1(1): 39-49.
12. Rosser AE, Dunnett SB. Neural transplantation in patients with Huntington's disease. CNS Drugs 2003; 17(12): 853-67.
13. Dunnett SB, Rosser AE. Clinical translation of cell transplantation in the brain. Curr Opin Organ Transplant 2011; 16(6): 632-9.
14. Barker RA, Mason SL, Harrower TP, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 2013; 84(6): 657-65.
15. Dunnett SB, Rosser AE. Cell transplantation for Huntington's disease should we continue? Brain Res Bull 2007; 72(2-3): 132-47.
16. Hotta Y. Ethical issues of the research on human embryonic stem cells. J Int Bioethique 2008; 19(3): 77-85, 124-5.
17. Kamm FM. Ethical issues in using and not using embryonic stem cells. Stem Cell Rev 2005; 1(4): 325-30.
18. Halevy T, Urbach A. Comparing ESC and iPSC-Based Models for Human Genetic Disorders. J Clin Med 2014; 3(4): 1146-62.
19. Gil-Perotin S, Duran-Moreno M, Cebrian-Silla A, Ramirez M, Garcia-Belda P, Garcia-Verdugo JM. Adult neural stem cells from the subventricular zone: a review of the neurosphere assay. Anat Rec (Hoboken) 2013; 296(9): 1435-52.
20. Deleyrolle LP, Reynolds BA. Isolation, expansion, and differentiation of adult Mammalian neural stem and progenitor cells using the neurosphere assay. Methods Mol Biol 2009; 549: 91-101.
21. Bonfanti L. Adult neurogenesis 50 years later: limits and opportunities in mammals. Front Neurosci 2016; 10: 44.
22. Lois C, Alvarez-Buylla A. Long-distance neuronal migration in the adult mammalian brain. Science 1994; 264(5162): 1145-8.
23. Gage FH. Mammalian neural stem cells. Science 2000; 287(5457): 1433-8.
24. Chaker Z, Codega P, Doetsch F. A mosaic world: puzzles revealed by adult neural stem cell heterogeneity. Wiley Interdiscip Rev Dev Biol 2016; 5(6): 640-58.
25. Donato R, Miljan EA, Hines SJ, et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci 2007; 8: 36.
26. Sanai N, Tramontin AD, Quinones-Hinojosa A, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004; 427(6976): 740-4.
27. van Strien ME, Sluijs JA, Reynolds BA, Steindler DA, Aronica E, Hol EM. Isolation of neural progenitor cells from the human adult subventricular zone based on expression of the cell surface marker CD271. Stem Cells Transl Med 2014; 3(4): 470-80.
28. Verwer RW, Hermens WT, Dijkhuizen P, et al. Cells in human postmortem brain tissue slices remain alive for several weeks in culture. Faseb J 2002; 16(1): 54-60.
29. Li Z, Oganesyan D, Mooney R, et al. L-MYC expression maintains self-renewal and prolongs multipotency of primary human neural stem cells. Stem Cell Reports 2016; 7(3): 483-95.
30. Ring KL, Tong LM, Balestra ME, et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012; 11(1): 100-9.
31. Ulrich H, do Nascimento IC, Bocsi J, Tarnok A. Immunomodulation in stem cell differentiation into neurons and brain repair. Stem Cell Rev 2015; 11(3): 474-86.
32. Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 2015; 13: 17.
33. Schwarz SC, Schwarz J. Translation of stem cell therapy for neurological diseases. Transl Res 2010; 156(3): 155-60.
34. Hsu YC, Chen SL, Wang DY, Chiu IM. Stem cell-based therapy in neural repair. Biomed J 2013; 36(3): 98-105.
35. Golas MM, Sander B. Use of human stem cells in Huntington disease modeling and translational research. Exp Neurol 2016; 278: 76-90.
36. Torrent R, De Angelis Rigotti F, Dell'Era P, et al. Using iPS Cells toward the understanding of Parkinson's Disease. J Clin Med 2015; 4(4): 548-66.
37. Mungenast AE, Siegert S, Tsai LH. Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. Mol Cell Neurosci 2016; 73: 13-31.
38. Liu H, Zeng F, Zhang M, et al. Emerging landscape of cell penetrating peptide in reprogramming and gene editing. J Control Release 2016; 226: 124-37.
39. Takahashi K, Yamanaka S. A developmental framework for induced pluripotency. Development 2015; 142(19): 3274-85.
40. Ku S, Soragni E, Campau E, et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 2010; 7(5): 631-7.
41. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465(7299): 808-12.
42. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120(9): 3127-36.
43. Zhang Y, Pak C, Han Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013; 78(5): 785-98.
44. De Filippis L, Halikere A, McGowan H, et al. Ethanol-mediated activation of the NLRP3 inflammasome in iPS cells and iPS cells-derived neural progenitor cells. Mol Brain 2016; 9(1): 51.
45. Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011; 480(7378): 547-51.
46. Wattanapanitch M, Klincumhom N, Potirat P, et al. Dual small-molecule targeting of SMAD signaling stimulates human induced pluripotent stem cells toward neural lineages. PLoS One 2014; 9(9): e106952.
47. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sade-lain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27(3): 275-80.
48. Adlakha YK, Seth P. The expanding horizon of MicroRNAs in cellular reprogramming. Prog Neurobiol 2017; 148: 21-39.
49. Richner M, Victor MB, Liu Y, Abernathy D, Yoo AS. MicroRNA-based conversion of human fibroblasts into striatal medium spiny neurons. Nat Protoc 2015; 10(10): 1543-55.
50. Victor MB, Richner M, Hermanstyne TO, et al. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron 2014; 84(2): 311-23.
51. Jesse S, Brathen G, Ferrara M, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand 2017; 135(1): 4-16.
52. Flores-Pajot MC, Ofner M, Do MT, Lavigne E, Villeneuve PJ. Childhood autism spectrum disorders and exposure to nitrogen dioxide, and particulate matter air pollution: a review and meta-analysis. Environ Res 2016; 151: 763-76.
53. Bottema-Beutel K. Associations between joint attention and language in autism spectrum disorder and typical development: a systematic review and meta-regression analysis. Autism Res 2016; 9(10): 1021-35.
54. Stone D, Niyonzima N, Jerome KR. Genome editing and the next generation of antiviral therapy. Hum Genet 2016; 135(9): 1071-82.
55. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471(7336): 63-7.
56. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467(7313): 285-90.
57. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8(1): 106-18.
58. Ma H, Morey R, O'Neil RC, et al. Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature 2014; 511(7508): 177-83.
59. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by tem- perature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 2011; 108(34): 14234-9.
60. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8(5): 409-12.
61. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4(6): 472-6.
62. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-30.
63. Schuster C, Kasper E, Machts J, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol 2013; 260(11): 2856-64.
64. Valori CF, Brambilla L, Martorana F, Rossi D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci 2014; 71(2): 287-97.
65. Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci 2014; 8: 117.
66. Rizzo F, Riboldi G, Salani S, et al. Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci 2014; 71(6): 999-1015.
67. Papadeas ST, Maragakis NJ. Advances in stem cell research for Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol 2009; 20(5): 545-51.
68. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995; 676(1): 25-40.
69. Nagai M, Aoki M, Miyoshi I, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001; 21(23): 9246-54.
70. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 2002; 99(3): 1604-9.
71. Matsumoto A, Okada Y, Nakamichi M, et al. Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res 2006; 83(1): 119-33.
72. Myszczynska M, Ferraiuolo L. New in vitro models to study amyotrophic lateral sclerosis. Brain Pathol 2016; 26(2): 258-65.
73. Amoroso MW, Croft GF, Williams DJ, et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci 2013; 33(2): 574-86.
74. Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002; 110(3): 385-97.
75. Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007; 500(1): 20-46.
76. Jordan PM, Ojeda LD, Thonhoff JR, et al. Generation of spinal motor neurons from human fetal brain-derived neural stem cells: role of basic fibroblast growth factor. J Neurosci Res 2009; 87(2): 318-32.
77. Wu P, Tarasenko YI, Gu Y, Huang LY, Coggeshall RE, Yu Y. Region-specific generation of cholinergic neurons from fetal human neural stem cells grafted in adult rat. Nat Neurosci 2002; 5(12): 1271-8.
78. Yang N, Ng YH, Pang ZP, Sudhof TC, Wernig M. Induced neuronal cells: how to make and define a neuron. Cell Stem Cell 2011; 9(6): 517-25.
79. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012; 4(145): 145ra04.
80. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008; 3(6): 649-57.
81. Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyper-excitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 2014; 7(1): 1-11.
82. Chen H, Qian K, Du Z, et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 2014; 14(6): 796-809.
83. Kiskinis E, Sandoe J, Williams LA, et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 2014; 14(6): 781-95.
84. Geevasinga N, Menon P, Ozdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat Rev Neurol. 2016; 12(11): 651-61.
85. Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J Physiol 2005; 563(Pt 3): 843-54.
86. Vucic S, Kiernan MC. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry 2010; 81(2): 222-7.
87. Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000; 12(10): 3567-74.
88. Almeida S, Gascon E, Tran H. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol 2013; 126(3): 385-99.
89. Donnelly CJ, Zhang PW, Pham JT, et al. RNA Toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013; 80(2): 415-28.
90. Sareen D, O'Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013; 5(208): 208ra149.
91. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72(2): 245-56.
92. Patterson M, Chan DN, Ha I, et al. Defining the nature of human pluripotent stem cell progeny. Cell Research 2011; 22(1): 178-93.
93. Batista LF, Pech MF, Zhong FL, et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011; 474(7351): 399-402.
94. Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008; 22(11): 1451-64.
95. Fakhoury M. Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener Dis 2015; 15(2): 63-9.
96. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302(5642): 113-7.
97. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26(1): 101-6.
98. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007; 10(5): 608-14.
99. Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10(5): 615-22.
100. Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008; 3(6): 637-48.
101. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52(1): 39-59.
102. Almer G, Guegan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001; 49(2): 176-85.
103. Kondo M, Shibata T, Kumagai T, et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A 2002; 99(11): 7367-72.
104. Allodi I, Comley L, Nichterwitz S, et al. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Scientific Reports, Published online: 16 May 2016; | doi: 10.1038/srep25960. 2016.
105. Nizzardo M, Simone C, Rizzo F, et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet 2014; 23(2): 342-54.
106. Nizzardo M, Bucchia M, Ramirez A, et al. iPSC-derived LewisX+CXCR4+beta1-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. Hum Mol Genet 2016; 25(15): 3152-3163.
107. Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102(6): E69.
108. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 2012; 199(5): 723-34.
109. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. 2006.
110. Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009; 1793(4): 684-96.
111. Schulze H, Sandhoff K. Lysosomal Lipid Storage Diseases. Cold Spring Harb Perspect Biol 32011.
112. Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 2009; 10(9): 623-35.
113. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 Suppl 5: v4-12.
114. Tomatsu S, Sawamoto K, Shimada T, et al. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs 2015; 3(11): 1279-90.
115. Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008; 146a(19): 2538-44.
116. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005; 32(4): 270-2.
117. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011; 6: 72.
118. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006; 116(11): 3070-82.
119. Biffi A, Cesani M. Human hematopoietic stem cells in gene therapy: pre-clinical and clinical issues. Curr Gene Ther 2008; 8(2): 135-46.
120. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341(6148): 1233158.
121. Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 2010; 107(17): 7886-91.
122. Xu M, Motabar O, Ferrer M, Marugan JJ, Zheng W, Ottinger EA. Disease models for the development of therapies for lysosomal storage diseases. Ann N Y Acad Sci 2016; 1371(1): 15-29.
123. Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 1162010. p. 5130-9.
124. Altarescu G, Renbaum P, Eldar-Geva T, et al. Preimplantation genetic diagnosis (PGD) for a treatable disorder: gaucher disease type 1 as a model. Blood Cells Mol Dis 2011; 46(1): 15-8.
125. Fusar Poli E, Zalfa C, D’Avanzo F, et al. Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved. Cell Death Dis 2013; 1: 12.
126. Zalfa C, Verpelli C, D’Avanzo F, et al. Oxidative damage with glial degeneration drives neuronal demise in MPSII disease. Cell Death Dis 2016; 7(8): e233.
127. Chen M, Tomkins DJ, Auerbach W, et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996; 12(4): 448-51.
128. Nelson DL, Gibbs RA. Genetics. The critical region in trisomy 21. Science 2004; 306(5696): 619-21.
129. Huang HP, Chuang CY, Kuo HC. Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases. Stem Cell Res Ther 2012; 3(4): 34.
130. Yu D, Swaroop M, Wang M, et al. Niemann-Pick disease type c: induced pluripotent stem cell-derived neuronal cells for modeling neural disease and evaluating drug efficacy. J Biomol Screen 2014; 19(8): 1164-73.
131. Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 2012; 13(11): 713-26.
132. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 2013; 18(21-22): 1067-73.
133. Aflaki E, Stubblefield BK, Maniwang E, et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med 2014; 6(240): 240ra73.
134. Tiscornia G, Vivas EL, Matalonga L, et al. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet 2013; 22(4): 633-45.
135. Tolar J, Park IH, Xia L, et al. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood 2011; 117(3): 839-47.
136. Varga E, Nemes C, Bock I, et al. Generation of Mucopolysaccharidosis type II (MPS II) human induced pluripotent stem cell (iPSC) line from a 3-year-old male with pathogenic IDS mutation. Stem Cell Res 2016; 17(3): 479-81.
137. Hashem SI, Perry CN, Bauer M, et al. Brief Report: oxidative stress mediates cardiomyocyte apoptosis in a human model of da-non disease and heart failure. Stem Cells 2015; 33(7): 2343-50.
138. Meneghini V, Frati G, Sala D, et al. Generation of human induced pluripotent stem cell-derived bona fide neural stem cells for ex vivo gene therapy of metachromatic leukodystrophy. Stem Cells Transl Med 2016; 6(2): 352-368.
139. Lemonnier T, Blanchard S, Toli D, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet 2011; 20(18): 3653-66.
140. Lieu PT, Fontes A, Vemuri MC, Macarthur CC. Generation of induced pluripotent stem cells with CytoTune, a non-integrating Sendai virus. Methods Mol Biol 2013; 997: 45-56.